These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Do we need new lipid-lowering agents in the era of PCSK9 inhibitors? Recent advances. Atar D; Langslet G; Tonstad S Kardiol Pol; 2022; 80(7-8):741-749. PubMed ID: 35521719 [TBL] [Abstract][Full Text] [Related]
4. Lipid-lowering agents for concurrent cardiovascular and chronic kidney disease. Katsiki N; Mikhailidis DP; Banach M Expert Opin Pharmacother; 2019 Nov; 20(16):2007-2017. PubMed ID: 31344332 [No Abstract] [Full Text] [Related]
5. Lipid-lowering therapies for cardiovascular disease prevention and management in primary care: PEER umbrella systematic review of systematic reviews. Dugré N; Lindblad AJ; Perry D; Allan GM; Braschi É; Falk J; Froentjes L; Garrison SR; Kirkwood JEM; Korownyk CS; McCormack JP; Moe SS; Paige A; Potter J; Thomas BS; Ton J; Young J; Weresch J; Kolber MR Can Fam Physician; 2023 Oct; 69(10):701-711. PubMed ID: 37833094 [TBL] [Abstract][Full Text] [Related]
6. Inter-Individual Variability in Lipid Response: A Narrative Review. Patnaik S; Pollevick ME; Lara-Breitinger KM; Stone NJ Am J Med; 2022 Dec; 135(12):1427-1433.e7. PubMed ID: 35878687 [TBL] [Abstract][Full Text] [Related]
17. Nonstatin therapies for management of dyslipidemia: a review. Sando KR; Knight M Clin Ther; 2015 Oct; 37(10):2153-79. PubMed ID: 26412799 [TBL] [Abstract][Full Text] [Related]
18. Effect of statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention: a meta-analysis of randomized trials. Koskinas KC; Siontis GCM; Piccolo R; Mavridis D; Räber L; Mach F; Windecker S Eur Heart J; 2018 Apr; 39(14):1172-1180. PubMed ID: 29069377 [TBL] [Abstract][Full Text] [Related]
19. [Modern lipid-lowering drugs-A means to counter the problem of undertreatment?]. Katzmann JL; Laufs U Inn Med (Heidelb); 2022 Dec; 63(12):1316-1322. PubMed ID: 35391570 [TBL] [Abstract][Full Text] [Related]
20. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons. Yadav K; Sharma M; Ferdinand KC Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]